MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    How does a diagnosis of Dementia with Parkinson’s influence future care provision?

    B. Mohamed, A. Rafeeq, J. Adenwalla, C. Thomas, S. Page, R. Lewis-Morton, T. Williams, S. Mahon (cardiff, United Kingdom)

    Objective: To describe the trajectory of Parkinson’s after the onset of dementia including setting of care, frailty levels and mortality rate. Background: Cardiff and Vale…
  • 2023 International Congress

    Incidence of childhood trauma in patients with functional movement disorder and its impact on motor symptoms severity

    L. Nováková, T. Serranová, P. Sojka, D. Voženílek (Praha, Czech Republic)

    Objective: To assess the impact of self-reported childhood traumatic experience on motor symptoms severity in a group of patients with functional movement disorder (FMD). Background:…
  • 2023 International Congress

    Consideration of age and initial putaminal rim segment in distinguishing multiple system atrophy parkinsonian type

    W. Lee (Seoul, Republic of Korea)

    Objective: To improve diagnostic performance in distinguishing multiple system atrophy parkinsonian type (MSA-p), we investigated the iron deposition pattern in the putaminal lateral margin of…
  • 2023 International Congress

    Does baseline expectation of benefit predict outcome in SURE-PD3, a Randomized, Double-Blind, Placebo-Controlled, Phase III trial of Inosine in Parkinson’s disease?

    T. Mestre, E. Macklin, A. Lang, M. Schwarzschild (Ottawa, Canada)

    Objective: To evaluate the association of patient-reported baseline expectation with efficacy outcomes in a randomized placebo-controlled trial (RCT) in PD. Background: Expectation of benefit can…
  • 2023 International Congress

    Is an integrated Parkinson’s Dementia Service the way forward?

    A. Rafeeq, C. Thomas, B. Mohamed, J. Adenwalla, S. Page, R. Lewis-Morton, S. Mahon, T. Williams (Cardiff, United Kingdom)

    Objective: To illustrate the role of a single team in managing all facets of Parkinson’s Background: The Cardiff and Vale Parkinson’s service is an integrated,…
  • 2023 International Congress

    Sexual health and sleep quality in women living with Parkinson’s disease: are we neglecting that?

    KCN. Nobrega, TSM. Martins, GFS. Santos, MEP. Piemonte (Sao Paulo, Brazil)

    Objective: To investigate the relationship between sexual health and sleep quality in PD. Background: Sexual dysfunction (SD) is a common yet under-reported, non-motor symptom (NMS)…
  • 2023 International Congress

    Clinical-based diagnosis and self-reported Parkinson’s disease in a population-based sample in southern Brazil

    G. Pereira, N. Soares, G. Marconi, C. Sangali, I. Pasuch, C. Bertocchi, N. Bruscato, J. Senger, A. Schumacher-Schuh, C. Rieder (Porto Alegre, Brazil)

    Objective: To report the frequency of self-reported PD and the diagnostic evaluation performed by clinical neurologists in a population-based cohort from south Brazil. Background: It…
  • 2023 International Congress

    Dystonia in the Middle East – The Cleveland Clinic Abu Dhabi Experience

    S. Mansoor, K. Waqar, M. Thomas, S. Mittal (Abu Dhabi, United Arab Emirates)

    Objective: This study aimed to evaluate the clinical spectrum of patients with dystonia seen at Cleveland Clinic Abu Dhabi Hospital (CCAD), a tertiary care center…
  • 2023 International Congress

    Clinical and molecular features of Tunisian patients with Biallelic mutations in Huntington’s Disease

    H. Nehdi, F. Nabli, Z. Saied, S. Ben Sassi, R. Amouri (Tunis, Tunisia)

    Objective: To investigate the clinical and molecular features of HD in homozygous versus heterozygous patients. Background: Huntington’s disease (HD) is a neurodegenerative autosomal dominant disorder…
  • 2023 International Congress

    Novel RAB39B stop mutation in patient with typical Early-Onset Parkinson’s disease

    J. Jacobson, C. Piat, O. Ross, R. Savica (Rochester, USA)

    Objective: N/A Background: RAB proteins are small guanosine triphosphatases (GTPases) that are ubiquitous and expressed in all cell types regulating vesicular transport and intracellular membrane…
  • « Previous Page
  • 1
  • …
  • 301
  • 302
  • 303
  • 304
  • 305
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley